A Study to Evaluate the Effect of Multiple Doses of Ridaforolimus (AP23573; MK8669) on the Single Dose Pharmacokinetics of Midazolam.
Phase of Trial: Phase I
Latest Information Update: 15 May 2014
At a glance
- Drugs Ridaforolimus (Primary) ; Midazolam
- Indications Haematological malignancies; Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 27 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 11 Mar 2011 Planned end date changed from 1 Dec 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.